IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Aug-2026
Active ingredients
durvalumab
Summary of proposed indication
IMFINZI (durvalumab), given together with enfortumab vedotin before bladder removal surgery, is proposed as a treatment for people with muscle-invasive bladder cancer (MIBC) who cannot have cisplatin-based chemotherapy or have chosen not to receive it. After surgery, IMFINZI is proposed to be continued on its own as follow-up treatment.
Application type
C (new indication)
Publication date
Aug-2026